Mon, October 31, 2022

David Nierengarten Downgraded (YMAB) to Hold and Held Target at $6 on, Oct 31st, 2022

David Nierengarten of Wedbush, Downgraded "Y-mAbs Therapeutics, Inc." (YMAB) to Hold and Held Target at $6 on, Oct 31st, 2022.

David, nor any peers, have made any analyst calls on YMAB in the last 4 months.

Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30